RJA
OVID icon

Raymond James & Associates’s Ovid Therapeutics OVID Stock Holding History

Raymond James & Associates’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-25,000
Closed -$82K – 3898
2023
Q2 		$82K Buy
+25,000
New +$84.9K ﹤0.01% 3667

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return

Raymond James & Associates's OVID Position: Q3 2023 in Review

Raymond James & Associates sold out of Ovid Therapeutics (OVID) in Q3 2023, closing a stake of 25,000 shares — an estimated $82K sold.

Raymond James & Associates first reported a position in OVID in Q2 2023 and held it in 1 quarter. The position peaked at $82K in Q2 2023. 64 funds tracked by Wall St. Rank hold OVID as of Q3 2023.

  • Raymond James & Associates reported no remaining Ovid Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Raymond James & Associates sold 25,000 Ovid Therapeutics shares in Q3 2023, an estimated $82K.
  • Raymond James & Associates first reported a position in Ovid Therapeutics in Q2 2023 and held it in 1 quarter.
  • Raymond James & Associates's Ovid Therapeutics position peaked at $82K in Q2 2023.
  • 64 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2023.

Based on Raymond James & Associates's 13F filing for Q3 2023, filed 24 Oct 2023.